IndustryCompany release

Alcon third-quarter sales rise 5% to $2.72bn as PowerVision impairment hits nine-month profit

Alcon Inc (ALC) · Tue 10 Nov 2026

Alcon reports 10% higher third-quarter net income, while a $505m charge for discontinuing PowerVision intraocular lens programmes drives a 35% fall in nine-month operating income.

Alcon has reported third-quarter 2026 net sales of $2.72bn, up 5%, in its interim report for the period ended 30 September 2026. Net income for the quarter was $260m, an increase of 10%.

The nine-month picture is weaker. Operating income fell 35% to $684m, chiefly because of a $505m impairment linked to the decision to discontinue the PowerVision intraocular lens (IOL) programmes. A $103m contingent consideration adjustment partly offset the charge.

Growth in the quarter was driven by Vision Care and by dry eye products, including Tryptyr and Systane. In Surgical, equipment launches such as Unity and Valeda contributed. Alcon noted that its US IOL sales faced competitive pressure.

The source material available gave no further detail on the reasons for the PowerVision discontinuation or on any regulatory implications.

What it means for your team

  • Discontinuation of the PowerVision IOL programmes removes a pipeline asset in a segment where Alcon reports competitive pressure in the US; teams tracking IOL competition should note the change.
  • Dry eye products, including the newly named Tryptyr, are cited as growth contributors, which is relevant to market-access teams following the category.
  • Surgical equipment launches such as Unity and Valeda are in the sales mix, so quality and post-market surveillance teams may wish to follow their rollout.

Company's press release (SEC filing): Alcon Inc ↗

Article written by VigiEye from the official source (Alcon Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →